• .
    • .
    • .
    • .

Protein Biomarker Discovery, Assay Development and Qualification Services

NextGen Sciences is a leading CRO in rapid biomarker discovery, measurement and qualification working with pharmaceutical, biotechnology, diagnostic and translational medicine organizations.

protein biomarker discovery for cancer, oncology, CNS diseases, AD, PD, MS, ALS, TBI using plasma, CSF, tissue
De novo and targeted assays for biomarker discovery
CSF biomarker assay for CNS, AD, PD, MS, ALS, TBI, brain injuries Targeted protein biomarker discovery and qualification in CNS diseases (AD, PD, HD, MS, ALS)
cancer biomarkers with plasma biomarker assay Targeted protein biomarker discovery and qualification in Oncology
protein custom assay development with CSF/Plasma with MRM, GeLCMS, SILAC technology
De novo discovery and quantitative, multiplexed assays

We provide customers with off-the-shelf protein biomarker discovery and qualification assays with a focus in Central Nervous System (CNS) and Oncology disease areas. Using mass spectrometry technology, we are able to shorten the timelines for assay development and to assay for proteins for which there are currently no effective commercial antibodies.